RNA-Based Therapeutic Technology.

Area of Science:

• Biotechnology
• Molecular Biology
• Immunotherapy

Background:

• RNA-based therapy is gaining traction post-COVID-19, contrasting with established DNA-based gene therapies like AAV and lentivirus vectors.
• DNA-based therapies offer persistent expression but lack precise control, potentially leading to adverse effects like cytokine release syndrome in cancer immunotherapy.
• Unmet medical needs persist where fine-tuned gene expression is crucial, highlighting limitations of current DNA-based approaches.

Purpose of the Study:

• To review the clinical applications and potential of RNA-based therapies.
• To compare RNA-based therapy with DNA-based gene therapy, focusing on control and safety.
• To explore RNA-based therapy's role in cancer immunotherapy, hematopoietic disorders, and inherited disorders.

Main Methods:

• Literature review of recent advancements in RNA-based and DNA-based therapeutic strategies.
• Comparative analysis of gene expression control and therapeutic efficacy between RNA and DNA modalities.
• Focused examination of clinical research in oncology, hematology, and genetic diseases.

Main Results:

• RNA-based therapies present a more controlled and potentially safer alternative to DNA-based gene therapies.
• The ability to modulate gene expression offers advantages in managing conditions like cancer immunotherapy-induced cytokine release syndrome.
• RNA therapy shows promise for diverse applications including hematopoietic and inherited disorders.

Conclusions:

• RNA-based therapy is a developing field with significant potential to address limitations of DNA-based gene therapy.
• Its tunable nature makes it suitable for applications requiring precise gene expression control, such as in immunotherapy and genetic disorders.
• Further research into RNA-based therapeutics is warranted for various clinical applications.